Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy

A post hoc analysis of RENAAL

D. De Zeeuw, D. Ramjit, Z. Zhang, A. B. Ribeiro, K. Kurokawa, J. P. Lash, J. Chan, G. Remuzzi, B. M. Brenner, S. Shahinfar

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Type 2 diabetes is becoming the leading cause of end-stage renal disease (ESRD) worldwide. Prevalence of ESRD and the antihypertensive response to renin-angiotensin system intervention are suggested to vary among different ethnicities. The Reduction in Endpoints in Non-insulin dependent diabetes mellitus with the Angiotensin II Antagonist Losartan (RENAAL) study, which included different ethnic groups, demonstrated a renoprotective effect of losartan. A post hoc analysis from RENAAL was performed where we examined in each ethnic group the ESRD risk, identified independent predictors for ESRD, effect of degree of baseline albuminuria, effect of 6-month antiproteinuric response to therapy on ESRD, and renoprotective effect of losartan assessed by albuminuria reduction and ESRD. Baseline albuminuria was the strongest predictor for ESRD in every ethnic group. Albuminuria reduction was associated with reduced risk of ESRD while losartan reduced albuminuria in every ethnic group. When accounting for independent predictors of ESRD, losartan exhibited renoprotection in all ethnic groups. In this type 2 diabetic population with nephropathy, baseline albuminuria is the predominant risk parameter for ESRD; early antiproteinuric effect of losartan predicts long-term renoprotection; and losartan appears to be renoprotective in all ethnic groups. Since the RENAAL study was not powered to determine ethnic responses, these results underline the need for prospective trials where the aim is renal protection among different ethnic groups.

Original languageEnglish
Pages (from-to)1675-1682
Number of pages8
JournalKidney International
Volume69
Issue number9
DOIs
Publication statusPublished - May 2006

Fingerprint

Diabetic Nephropathies
Ethnic Groups
Chronic Kidney Failure
Losartan
Albuminuria
Kidney
Type 2 Diabetes Mellitus
Renin-Angiotensin System
Angiotensin II
Antihypertensive Agents

Keywords

  • Albuminuria
  • ESRD
  • Ethnicity
  • Losartan
  • Proteinuria
  • Type 2 diabetes

ASJC Scopus subject areas

  • Nephrology

Cite this

De Zeeuw, D., Ramjit, D., Zhang, Z., Ribeiro, A. B., Kurokawa, K., Lash, J. P., ... Shahinfar, S. (2006). Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: A post hoc analysis of RENAAL. Kidney International, 69(9), 1675-1682. https://doi.org/10.1038/sj.ki.5000326

Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy : A post hoc analysis of RENAAL. / De Zeeuw, D.; Ramjit, D.; Zhang, Z.; Ribeiro, A. B.; Kurokawa, K.; Lash, J. P.; Chan, J.; Remuzzi, G.; Brenner, B. M.; Shahinfar, S.

In: Kidney International, Vol. 69, No. 9, 05.2006, p. 1675-1682.

Research output: Contribution to journalArticle

De Zeeuw, D, Ramjit, D, Zhang, Z, Ribeiro, AB, Kurokawa, K, Lash, JP, Chan, J, Remuzzi, G, Brenner, BM & Shahinfar, S 2006, 'Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: A post hoc analysis of RENAAL', Kidney International, vol. 69, no. 9, pp. 1675-1682. https://doi.org/10.1038/sj.ki.5000326
De Zeeuw, D. ; Ramjit, D. ; Zhang, Z. ; Ribeiro, A. B. ; Kurokawa, K. ; Lash, J. P. ; Chan, J. ; Remuzzi, G. ; Brenner, B. M. ; Shahinfar, S. / Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy : A post hoc analysis of RENAAL. In: Kidney International. 2006 ; Vol. 69, No. 9. pp. 1675-1682.
@article{918ed4a8157b4c13884d76e9e9d0fa84,
title = "Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: A post hoc analysis of RENAAL",
abstract = "Type 2 diabetes is becoming the leading cause of end-stage renal disease (ESRD) worldwide. Prevalence of ESRD and the antihypertensive response to renin-angiotensin system intervention are suggested to vary among different ethnicities. The Reduction in Endpoints in Non-insulin dependent diabetes mellitus with the Angiotensin II Antagonist Losartan (RENAAL) study, which included different ethnic groups, demonstrated a renoprotective effect of losartan. A post hoc analysis from RENAAL was performed where we examined in each ethnic group the ESRD risk, identified independent predictors for ESRD, effect of degree of baseline albuminuria, effect of 6-month antiproteinuric response to therapy on ESRD, and renoprotective effect of losartan assessed by albuminuria reduction and ESRD. Baseline albuminuria was the strongest predictor for ESRD in every ethnic group. Albuminuria reduction was associated with reduced risk of ESRD while losartan reduced albuminuria in every ethnic group. When accounting for independent predictors of ESRD, losartan exhibited renoprotection in all ethnic groups. In this type 2 diabetic population with nephropathy, baseline albuminuria is the predominant risk parameter for ESRD; early antiproteinuric effect of losartan predicts long-term renoprotection; and losartan appears to be renoprotective in all ethnic groups. Since the RENAAL study was not powered to determine ethnic responses, these results underline the need for prospective trials where the aim is renal protection among different ethnic groups.",
keywords = "Albuminuria, ESRD, Ethnicity, Losartan, Proteinuria, Type 2 diabetes",
author = "{De Zeeuw}, D. and D. Ramjit and Z. Zhang and Ribeiro, {A. B.} and K. Kurokawa and Lash, {J. P.} and J. Chan and G. Remuzzi and Brenner, {B. M.} and S. Shahinfar",
year = "2006",
month = "5",
doi = "10.1038/sj.ki.5000326",
language = "English",
volume = "69",
pages = "1675--1682",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy

T2 - A post hoc analysis of RENAAL

AU - De Zeeuw, D.

AU - Ramjit, D.

AU - Zhang, Z.

AU - Ribeiro, A. B.

AU - Kurokawa, K.

AU - Lash, J. P.

AU - Chan, J.

AU - Remuzzi, G.

AU - Brenner, B. M.

AU - Shahinfar, S.

PY - 2006/5

Y1 - 2006/5

N2 - Type 2 diabetes is becoming the leading cause of end-stage renal disease (ESRD) worldwide. Prevalence of ESRD and the antihypertensive response to renin-angiotensin system intervention are suggested to vary among different ethnicities. The Reduction in Endpoints in Non-insulin dependent diabetes mellitus with the Angiotensin II Antagonist Losartan (RENAAL) study, which included different ethnic groups, demonstrated a renoprotective effect of losartan. A post hoc analysis from RENAAL was performed where we examined in each ethnic group the ESRD risk, identified independent predictors for ESRD, effect of degree of baseline albuminuria, effect of 6-month antiproteinuric response to therapy on ESRD, and renoprotective effect of losartan assessed by albuminuria reduction and ESRD. Baseline albuminuria was the strongest predictor for ESRD in every ethnic group. Albuminuria reduction was associated with reduced risk of ESRD while losartan reduced albuminuria in every ethnic group. When accounting for independent predictors of ESRD, losartan exhibited renoprotection in all ethnic groups. In this type 2 diabetic population with nephropathy, baseline albuminuria is the predominant risk parameter for ESRD; early antiproteinuric effect of losartan predicts long-term renoprotection; and losartan appears to be renoprotective in all ethnic groups. Since the RENAAL study was not powered to determine ethnic responses, these results underline the need for prospective trials where the aim is renal protection among different ethnic groups.

AB - Type 2 diabetes is becoming the leading cause of end-stage renal disease (ESRD) worldwide. Prevalence of ESRD and the antihypertensive response to renin-angiotensin system intervention are suggested to vary among different ethnicities. The Reduction in Endpoints in Non-insulin dependent diabetes mellitus with the Angiotensin II Antagonist Losartan (RENAAL) study, which included different ethnic groups, demonstrated a renoprotective effect of losartan. A post hoc analysis from RENAAL was performed where we examined in each ethnic group the ESRD risk, identified independent predictors for ESRD, effect of degree of baseline albuminuria, effect of 6-month antiproteinuric response to therapy on ESRD, and renoprotective effect of losartan assessed by albuminuria reduction and ESRD. Baseline albuminuria was the strongest predictor for ESRD in every ethnic group. Albuminuria reduction was associated with reduced risk of ESRD while losartan reduced albuminuria in every ethnic group. When accounting for independent predictors of ESRD, losartan exhibited renoprotection in all ethnic groups. In this type 2 diabetic population with nephropathy, baseline albuminuria is the predominant risk parameter for ESRD; early antiproteinuric effect of losartan predicts long-term renoprotection; and losartan appears to be renoprotective in all ethnic groups. Since the RENAAL study was not powered to determine ethnic responses, these results underline the need for prospective trials where the aim is renal protection among different ethnic groups.

KW - Albuminuria

KW - ESRD

KW - Ethnicity

KW - Losartan

KW - Proteinuria

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=33646523408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646523408&partnerID=8YFLogxK

U2 - 10.1038/sj.ki.5000326

DO - 10.1038/sj.ki.5000326

M3 - Article

VL - 69

SP - 1675

EP - 1682

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 9

ER -